Background/Aims: The MT2 melatonin receptor is a potential target for treating circadian rhythm sleep disorders. This study aims to characterize the recently identified MT2 melatonin receptor agonist. Methods: The pharmacological properties of the MT2 melatonin receptor-selective agonist as exemplified by compound 1 [N-(2-[7-benzyl-1,6-dihydro-2H-indeno(5,4-b)furan-8-yl]ethyl)acetamide] were evaluated by use of cell-free binding and cell-based functional assays. Results: Competition binding assays using 2-[125I]iodomelatonin revealed rapid, reversible, and high-affinity binding of compound 1 to human, mouse, and rat MT2 melatonin receptors. cAMP, ERK1/2, and PathHunter β-arrestin recruitment assays revealed partial agonist activities. However, compound 1 induced a more intense internalization of human MT2 melatonin receptor than melatonin. Based on studies using structurally related analogs of compound 1, we further demonstrated that the extent of internalization is independent of the intrinsic efficacy of agonists. Conclusion: These findings provide novel insights into the relationship between intrinsic agonist efficacy and agonist-induced internalization and demonstrate that compound 1 could serve as a pharmacological tool for future studies to elucidate the detailed molecular mechanism of MT2 receptor internalization.

Keywords:
Melatonin, Sleep disorder, G protein-coupled receptor, Partial agonist, Internalization
1.
Reiter RJ: Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991;12:151-180.
2.
Foulkes NS, Borjigin J, Snyder SH, Sassone-Corsi P: Rhythmic transcription: the molecular basis of circadian melatonin synthesis. Trends Neurosci 1997;20:487-492.
3.
Cassone VM: Effects of melatonin on vertebrate circadian systems. Trends Neurosci 1990;13:457-464.
4.
Pevet P, Bothorel B, Slotten H, Saboureau M: The chronobiotic properties of melatonin. Cell Tissue Res 2002;309:183-191.
5.
Petrie K, Conaglen JV, Thompson L, Chamberlain K: Effect of melatonin on jet lag after long haul flights. BMJ 1989;298:705-707.
6.
Oxenkrug GF, Requintina PJ: Melatonin and jet lag syndrome: experimental model and clinical implications. CNS Spectr 2003;8:139-148.
7.
Simon RD: Shift work disorder: clinical assessment and treatment strategies. J Clin Psychiatry 2012;73:e20.
8.
Lack LC, Wright HR: Clinical management of delayed sleep phase disorder. Behav Sleep Med 2007;5:57-76.
9.
van Geijlswijk IM, Korzilius HP, Smits MG: The use of exogenous melatonin in delayed sleep phase disorder: a meta-analysis. Sleep 2010;33:1605-1614.
10.
Reppert SM, Weaver DR, Ebisawa T: Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 1994;13:1177-1185.
11.
Reppert SM, Godson C, Mahle CD, Weaver DR, Slaugenhaupt SA, Gusella JF: Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci USA 1995;92:8734-8738.
12.
Tan DX, Manchester LC, Terron MP, Flores LJ, Tamura H, Reiter RJ: Melatonin as a naturally occurring co-substrate of quinone reductase-2, the putative MT3 melatonin membrane receptor: hypothesis and significance. J Pineal Res 2007;43:317-320.
13.
Cutando A, Aneiros-Fernandez J, Lopez-Valverde A, Arias-Santiago S, Aneiros-Cachaza J, Reiter RJ: A new perspective in oral health: potential importance and actions of melatonin receptors MT1, MT2, MT3, and RZR/ROR in the oral cavity. Arch Oral Biol 2011;56:944-950.
14.
Morgan PJ, Barrett P, Howell HE, Helliwell R: Melatonin receptors: localization, molecular pharmacology and physiological significance. Neurochem Int 1994;24:101-146.
15.
Liu C, Weaver DR, Jin X, Shearman LP, Pieschl RL, Gribkoff VK, Reppert SM: Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 1997;19:91-102.
16.
Dubocovich ML, Yun K, Al-Ghoul WM, Benloucif S, Masana MI: Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. FASEB J 1998;12:1211-1220.
17.
Dubocovich ML, Markowska M: Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005;27:101-110.
18.
Koike T, Hoashi Y, Takai T, Nakayama M, Yukuhiro N, Ishikawa T, Hirai K, Uchikawa O: 1,6-Dihydro-2H-indeno[5,4-b]furan derivatives: design, synthesis, and pharmacological characterization of a novel class of highly potent MT2-selective agonists. J Med Chem 2011;54:3436-3444.
19.
Nonno R, Pannacci M, Lucini V, Angeloni D, Fraschini F, Stankov BM: Ligand efficacy and potency at recombinant human MT2 melatonin receptors: evidence for agonist activity of some mt1-antagonists. Br J Pharmacol 1999;127:1288-1294.
20.
Mattson RJ, Catt JD, Keavy D, Sloan CP, Epperson J, Gao Q, Hodges DB, Iben L, Mahle CD, Ryan E, Yocca FD: Indanyl piperazines as melatonergic MT2 selective agents. Bioorg Med Chem Lett 2003;13:1199-1202.
21.
Epperson JR, Deskus JA, Gentile AJ, Iben LG, Ryan E, Sarbin NS: 4-Substituted anilides as selective melatonin MT2 receptor agonists. Bioorg Med Chem Lett 2004;14:1023-1026.
22.
Osmond RI, Sheehan A, Borowicz R, Barnett E, Harvey G, Turner C, Brown A, Crouch MF, Dyer AR: GPCR screening via ERK 1/2: a novel platform for screening G protein-coupled receptors. J Biomol Screen 2005;10:730-737.
23.
Lohse MJ, Benovic JL, Codina J, Caron MG, Lefkowitz RJ: β-Arrestin: a protein that regulates β-adrenergic receptor function. Science 1990;248:1547-1550.
24.
Conner DA, Mathier MA, Mortensen RM, Christe M, Vatner SF, Seidman CE, Seidman JG: β-Arrestin1 knockout mice appear normal but demonstrate altered cardiac responses to β-adrenergic stimulation. Circ Res 1997;81:1021-1026.
25.
Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT: Enhanced morphine analgesia in mice lacking β-arrestin 2. Science 1999;286:2495-2498.
26.
Eglen RM: Enzyme fragment complementation: a flexible high throughput screening assay technology. Assay Drug Dev Technol 2002;1:97-104.
27.
Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S, Kawamata Y, Hinuma S, Miyamoto M: Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 2005;48:301-310.
28.
Gibelin P, Bossan P, Ferrari E, Drici M, Morand P: Treatment of chronic heart insufficiency with dobutamine: value and limitations (in French). Presse Med 1992;21:1680-1684.
29.
Haney S, Hancox RJ: Recovery from bronchoconstriction and bronchodilator tolerance. Clin Rev Allergy Immunol 2006;31:181-196.
30.
Gerdin MJ, Masana MI, Ren D, Miller RJ, Dubocovich ML: Short-term exposure to melatonin differentially affects the functional sensitivity and trafficking of the hMT1 and hMT2 melatonin receptors. J Pharmacol Exp Ther 2003;304:931-939.
31.
Su YF, Harden TK, Perkins JP: Catecholamine-specific desensitization of adenylate cyclase: evidence for a multistep process. J Biol Chem 1980;255:7410-7419.
32.
January B, Seibold A, Whaley B, Hipkin RW, Lin D, Schonbrunn A, Barber R, Clark RB: β2-Adrenergic receptor desensitization, internalization, and phosphorylation in response to full and partial agonists. J Biol Chem 1997;272:23871-23879.
33.
Kovoor A, Celver JP, Wu A, Chavkin C: Agonist induced homologous desensitization of μ-opioid receptors mediated by G protein-coupled receptor kinases is dependent on agonist efficacy. Mol Pharmacol 1998;54:704-711.
34.
Clark RB, Knoll BJ, Barber R: Partial agonists and G protein-coupled receptor desensitization. Trends Pharmacol Sci 1999;20:279-286.
35.
Luk T, Jin W, Zvonok A, Lu D, Lin XZ, Chavkin C, Makriyannis A, Mackie K: Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist. Br J Pharmacol 2004;142:495-500.
36.
Alvarez VA, Arttamangkul S, Dang V, Salem A, Whistler JL, von Zastrow M, Grandy DK, Williams JT: μ-Opioid receptors: ligand-dependent activation of potassium conductance, desensitization, and internalization. J Neurosci 2002;22:5769-5776.
37.
Shi Y, Sheng R, Zhong T, Xu Y, Chen X, Yang D, Sun Y, Yang F, Hu Y, Zhou N: Identification and characterization of ZEL-H16 as a novel agonist of the histamine H3 receptor. PLoS One 2012;7:e42185.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.